HALLE/SAALE, Germany, February 7, 2014 – Probiodrug AG (Probiodrug), today announced that Dr Konrad Glund, the Company’s chief executive officer, will provide an update of corporate and clinical accomplishments at the annual BIO CEO & Investor Conference. Dr Glund’s presentation will take place on Monday, February 10, at 1:30 pm Eastern Time at the Waldorf Astoria hotel in New York.
The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded and select private biotech companies. The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities. For more information on the conference, please visit www.bio.org/events/conferences/bio-ceo-investor-conference.
Probiodrug is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic solutions to treat people with Alzheimer’s disease. The Company has medical use and composition of matter patents related to the inhibition of glutaminyl cyclase, providing the Company with a dominant position in this field of research. Probiodrug is backed by institutions such as BB Biotech, Edmond de Rothschild Investment Partners, Goodvent/IBG, HBM, TVM Capital, Life Sciences Partners, Biogen Idec New Ventures, CFH Group, funds managed by Wellington Management and private investors.
Probiodrug’s core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes which play a central role in the maturation of hormones. Probiodrug was founded in 1997 by Prof. Dr. Hans-Ulrich Demuth and Dr. Konrad Glund. For more information, please visit www.probiodrug.de.
Dr. Konrad Glund, CEO
Tel: +49 (345) 555-9900